Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355

Pembrolizumab plus chemotherapy improved progression‐free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple‐negative breast cancer with tumor programmed cell death ligand 1 (PD‐L1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattori, Masaya, Masuda, Norikazu, Takano, Toshimi, Tsugawa, Koichiro, Inoue, Kenichi, Matsumoto, Koji, Ishikawa, Takashi, Itoh, Mitsuya, Yasojima, Hiroyuki, Tanabe, Yuko, Yamamoto, Keiko, Suzuki, Masato, Pan, Wilbur, Cortes, Javier, Iwata, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225213/
https://www.ncbi.nlm.nih.gov/pubmed/36916728
http://dx.doi.org/10.1002/cam4.5757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225213/
https://www.ncbi.nlm.nih.gov/pubmed/36916728
http://dx.doi.org/10.1002/cam4.5757

Ejemplares similares